Motilal Oswal's research report on Aurobindo Pharma
Aurobindo Pharma (ARBP) reported an in-line performance in 2QFY26. Interestingly, the quarter saw lower contribution from g-Revlimid compared to earlier quarters. ARBP has been delivering robust growth momentum in EU market and is close to achieving annualized revenue of EUR1b. Product introductions and its increasing reach can help ARBP sustain growth prospects in EU.
Outlook
We largely maintain our estimates for FY26/FY27/FY28. We value ARBP at 16x 12M forward earnings to arrive at a TP of INR1,350.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
